Shots:
- Health Canada has approved Steqeyma injection & Steqeyma I.V. (injection, solution for IV infusion), biosimilar versions of Stelara (ustekinumab) to treat adults with moderate to severe active Crohn’s disease & plaque PsO as well as active psoriatic arthritis
- Approval was supported by the P-III trial of Steqeyma vs Stelara, with the 1EP as rate of change in the psoriasis area & severity index for skin symptoms after 52wks. The efficacy was similar in patients who switched to Steqeyma at wk.16
- Steqeyma, an IL-12 & -23 antagonist, is accessible in both IV [130mg/26 mL (5mg/mL) solution in a single-dose vial] & SC (45mg/0.5mL or 90mg/1mL solution in a single-dose, prefilled syringe) formulations
Ref: Businesswire | Image: Celltrion | Press Release
Related News:- Xbrane Biopharma Reclaims Rights of BIIB801 (Biosimilar, Cimzia) from Biogen
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
